One of the big three preclinical responders to CB receptor targeted therapies are autoimmune and auto-inflammatory diseases. Many cannabinoids are being studied for their anti-inflammatory and immune system mediation, and they are proving to be a potentially powerful tool in the fight for viable treatments. Currently, research shows that many cannabinoids suppress cytokine production, and can help suppress disease activity. A 1:1 THC:CBD tincture called Sativex is already being used for patients with multiple sclerosis in England, Wales, Canada, and other European countries.
This information is not intended to be medical or legal advice. These are studies and information that you can bring to your medical team so you can make informed decisions.